类风湿关节炎患者血清炎性因子、ANCA水平与血管内皮损伤标志物的相关性分析

目的:探讨类风湿关节炎(RA)患者血清炎性因子及抗中性粒细胞胞浆抗体(ANCA)水平与血管内皮损伤的相关性。方法:106例RA患者,分为活动组(83例)和缓解组(23例),55例健康人群作为对照,采用ELISA检测各组血清炎性因子白介素-1β(IL-1β)、白介素-6(IL-6)、白介素-17(IL-17)、肿瘤坏死因子-α(TNF-α)及血管内皮损伤标志物-血管性血友病因子(vWF)、可溶性细胞间黏附分子-1(sI-CAM-1)及血管内皮黏附分子-1(sVCAM-1)水平;采用间接免疫荧光法(IIF)检测各组血清ANCA阳性率。比较各组上述指标水平差异,分析两组RA患者炎性因子水平、ANCA阳性率与血管内皮损伤标志物水平的相关性。结果:RA活动组IL-6、TNF-α、vWF、sICAM-1、sVCAM-1血清水平均高于对照组(P<0.05);RA缓解组IL-6、vWF水平均低于RA活动组(P<0.05),但vWF、sVCAM-1水平仍显著高于对照组(P<0.01);RA患者IL-6、IL-1β、IL-17与血管内皮损伤标志物有不同程度的相关性;RA患者活动组ANCA阳性率为32.5%,显著高于对照组(P<0.01);ANCA阳性患者vWF水平高于ANCA阴性患者(P<0.05)。结论:RA活动期患者存在较明显血管内皮损伤,这种损伤与高水平的炎性因子及ANCA阳性表达有关。     

氟伐他丁对ACS患者CRP及sICAM-1、sVCAM-1的影响

目的:研究氟伐他丁对急性冠状动脉综合征(ACS)患者血清C-反应蛋白(CRP)及可溶性细胞黏附分子-1(sICAM-1)、可溶性血管细胞黏附分子-1(sVCAM-1)的影响.方法:采用随机、对照的方法将109例ACS患者分为氟伐他丁组(55例)和常规治疗组(54例),另选50例健康人为对照组,测定治疗前、治疗8周后血清CRP、sICAM-1、sVCAM-1的变化.结果:①ACS患者血清CRP、sICAM-1、sVCAM-1水平明显高于对照组(P＜0.01).②氟伐他丁组治疗8周后血清CRP、sICAM-1、sVCAM-1水平显著降低(P＜0.01).而常规治疗组治疗后无显著变化.结论:氟伐他丁对ACS患者有抗炎抗细胞黏附作用.     

血清睾酮水平与男性冠心病的关系

目的:探讨血清睾酮(T)水平与男性冠心病(CHD)的关系。方法:根据冠脉造影结果将126例男性患者分为CHD组(91例)和对照组(35例)。采用化学发光法平行检测两组血清T水平,同时分别对<60岁和≥60岁以及不同支数冠脉狭窄患者的血清T水平进行比较。结果:CHD组患者血清T水平显著低于对照组(P<0.05),尤以≥60岁的老年男性患者血清T水平更低(P<0.05);单支与多支冠脉狭窄患者血清T水平差异无统计学意义。结论:低水平血清T与老年(≥60岁)男性CHD有关,但与冠脉狭窄支数没有明显关系。     

sICAM-1和sVCAM-1与乙肝病毒标志物关系的研究

目的探讨可溶性血管内皮细胞问黏附分子1(sVCAM-1)和可溶性细胞问黏附分子1(sICAM-1)的水平与乙肝病毒标志物之间的关系。方法用ELISA法测定乙肝病毒标志物、sVCAM-1、sICAM-1，用PER法定量测定HBV-DNA的含量。结果HBVM阳性者，除HBsAb阳性者外，其血清sVCAM-1、sICAM-1水平较全阴性者均有较明显的升高，但升高的各组间无明显差异；sICAM-1与ALT呈正相关(r=0．652)，与HBA-DNA呈负相关(r=-0．498)；sVCAM-1与ALT、HBV-DNA的相关系数r分别为0．191、-0．027。结论1、乙肝病毒感染者血清sVCAM-1、sICAM-1有明显的升高，各组间无明显差异。2、sICAM-1的水平可以反应肝脏的损害程度和HBV-DNA的复制情况。     

丁二磺酸腺苷蛋氨酸辅助治疗胆汁淤积性肝炎的疗效评价

目的:探究丁二磺酸腺苷蛋氨酸辅助治疗胆汁淤积性肝炎(Cholestatic hepatitis,CH)的效果.方法:选取2019年1月至2020年12月我院收治的100例CH患者,随机分2组(n=50).对照组静滴门冬氨酸钾镁20 mL Qd治疗,研究组在此基础上静滴丁二磺酸腺苷蛋氨酸1000 mg Qd治疗.对比2组治疗28 d后总有效率,并于治疗前、治疗28 d后以全自动生化分析仪测定肝功能及肝纤维化指标,酶联免疫吸附法测定血清可溶性细胞间黏附分子-1(Serum soluble intercellular adhesionmolecule-1,sICAM-1)、血管细胞黏附分子-1(Soluble vascular cell adhesion molecule-1,sVCAM-1,sVCAM-1)水平.结果:与对照组相比,研究组总有效率更高(P<0.05);与治疗前相比,各治疗组血清GGT、AST、TBIL、ALT、sICAM-1、sVCAM-1、IV-C、PCIII、HA水平均明显降低(P<0.05),其中研究组效果更为显著(P<0.05).结论:丁二磺酸腺苷蛋氨酸对CH患者具有显著的辅助治疗作用,可改善肝功能及肝纤维化,利于患者恢复.     

阿托伐他汀对冠心病患者外周血单核细胞/巨噬细胞清道夫受体的影响

目的：观察冠心病患者外周血单核细胞（PBMs）转化巨噬细胞清道夫受体活性及血清炎性因子(包括CRP、sICAM-1 、sVCAM-1)的变化及阿托伐他汀对清道夫受体活性的影响，探讨炎性因子水平与清道夫受体活性关系及他汀类药物稳定粥样硬化斑块的可能机制。 方法： 75例血脂正常冠心病患者分为稳定性心绞痛组、不稳定性心绞痛组、急性心肌梗死3组，29例健康人作为对照。测定所有观察对象血清C反应蛋白、可溶性细胞间黏附分子（sICAM-1）、血管细胞黏附分子（sVCAM-1）水平；并在体外分离培养PBMs并转化为巨噬细胞, 观察阿托伐他汀对其表达清道夫受体的影响。 结果： 巨噬细胞清道夫受体活性及血清C反应蛋白、sICAM-1、sVCAM-1水平，急性心肌梗死组>不稳定性心绞痛组>稳定性心绞痛组>对照组。阿托伐他汀能下调冠心病患者PBMs源性巨噬细胞清道夫受体活性。冠心病患者PBMs源性巨噬细胞清道夫受体活性与C反应蛋白、sICAM-1、sVCAM-1呈正相关。 结论： PBMs源性巨噬细胞清道夫受体活性可作为易损斑块活动程度的监测指标；阿托伐他汀可抑制冠心病患者血PBMs源性巨噬细胞清道夫受体活性。     

慢性乙型肝炎患者血清黏附分子和肝功能关系的研究

<正>目的:研究慢性乙型肝炎患者血清黏附分子和肝功能的关系,探索黏附分子对慢性乙肝发病的作用。方法:选用180例慢性乙型肝炎患者,清晨空腹采取肘静脉血,分离血清,采用ELISA检测血清中循环黏附分子sICAM-1和sVCAM-1水平,同时检测血清丙氨酸氨基转移酶(ALT)、天门冬氨酸氨基转移酶(AST)等     

可溶性细胞间黏附分子-1在原发性肝癌患者血清中的表达及其与肝纤维化的关系

目的:探讨可溶性细胞间黏附分子-1(sICAM-1)在原发性肝癌(PHC)患者血清中的水平及其与肝纤维化的关系。方法:采用ELISA方法测定45例PHC患者、30例良性肿瘤患者和35例健康查体者血清sICAM-1和肝纤维化四项(PCⅢ、Ⅳ-C、LN、HA)水平,并分析sICAM-1与肝纤维化之间的关系。结果:PHC组血清sICAM-1和肝纤维化四项(PCⅢ、Ⅳ-C、LN、HA)水平均显著高于良性肿瘤组和正常对照组,相比较有显著性差异(P<0.05);而良性肿瘤组和正常对照组各指标比较差异无统计学意义(P>0.05);血清sICAM-1含量与PCⅢ、Ⅳ-C、LN、HA含量呈显著正相关性(r=0.683、0.575、0.573、0.539,P<0.05)。结论:检测血清sICAM-1的水平对判定PHC患者的病情、为肝癌的早期诊断和治疗有着重要的临床意义。     

急性冠脉综合征病人血清中E-选择素、可溶性细胞间粘附分子-1和可溶性血管细胞间粘附分子-1含量的变化

目的:探讨急性冠脉综合征病人血中粘附分子表达在识别不稳定冠脉粥样硬化斑块中的作用。方法:选取急性冠脉综合征病人80例, 其中急性心肌梗死病人40例, 不稳定心绞痛病人40例, 急性冠脉综合征病人经治疗4个月后进行随访, 同时选取正常对照40例。采用酶联免疫法(ELISA)测定血清中E-选择素、可溶性细胞间粘附分子-1(sICAM-1)和可溶性血管细胞间粘附分子-1(sVCAM-1)的水平。结果:外周血中E-选择素、sICAM-1、sVCAM-1水平在急性心肌梗死组、不稳定心绞痛组显著高于对照组, 除sVCAM-1外在随访时明显降低。结论:外周血中E-选择素、sICAM-1的水平可能作为诊断和预测急性冠脉综合征发生的敏感指标, 并可以反映冠脉粥样硬化斑块的稳定情况。     

冠心病患者血清胱抑素C、一氧化氮、超氧化物歧化酶及超敏C反应蛋白水平变化及与冠脉狭窄程度的相关性

目的:分析血清胱抑素C(CysC)、一氧化氮(NO)、超氧化物歧化酶(SOD)及超敏C反应蛋白(hs-CRP)水平与冠状动脉狭窄程度的关系及其临床意义。方法:162例心血管病患者依据冠脉造影结果分为对照组(冠脉狭窄50%,n=40);单支病变组(一支冠脉狭窄≥50%,n=44);双支病变组(两支冠脉狭窄≥50%,n=43);多支病变组(两支以上冠脉狭窄≥50%,n=35)。对四组患者进行冠脉狭窄Gensini积分及血清CysC、NO、SOD及hs-CRP水平检测,分析冠心病患者各指标变化及其与Gensini积分的相关性。结果:单支病变组、双支病变组、多支病变组的CysC和hs-CRP水平均高于对照组(P0.05),并依次递增;单支病变组、双支病变组、多支病变组的NO及SOD水平均低于对照组(P0.05),并依次递减。冠心病患者Gensini积分与血清CysC和hs-CRP水平呈正相关,相关系数分别为0.473,0.429(P0.05);与NO和SOD水平呈负相关,相关系数分别为-0.356,-0.384(P0.05)。结论:冠心病患者冠脉狭窄程度的增加与CysC、hs-CRP水平升高及NO、SOD水平降低有明显相关性。     

Increased plasma concentrations of sICAM-1, sVCAM-1 and sELAM-1 in patients with Plasmodium falciparum or P. vivax malaria and association with disease severity.

Increased serum concentrations of soluble intercellular adhesion molecule-1 (sICAM-1), soluble endothelial leucocyte adhesion molecule-1 (sELAM-1) and soluble vascular cell adhesion molecule-1 (sVCAM-1) were detected in Danish malaria patients infected with sequestering Plasmodium falciparum or non-sequestering P. vivax parasites, as well as in patients with sepsis or meningitis. Levels of soluble adhesion molecules remained elevated in the P. falciparum patients for several weeks after initiation of treatment. Plasma concentrations of sICAM-1, sVCAM-1 and sELAM-1 were higher in Gambian children with severe P. falciparum malaria than in children with mild malaria. Plasma levels of sVCAM-1 and sELAM-1 were significantly correlated. Plasma levels of sELAM-1 and sVCAM-1 may reflect endothelial inflammatory reactions and these reactions may be harmful for humans infected with malaria parasites.     

Does infection with Chlamydia pneumoniae and/or Helicobacter pylori increase the expression of endothelial cell adhesion molecules in humans?

Objective   To investigate if Chlamydia pneumoniae and/or Helicobacter pylori seropositivity is associated with elevated levels of soluble endothelial cell adhesion molecules (sCAMs) as markers of atherosclerotic activity.
Methods   Immunoglobulin A (IgA) and IgG antibodies to the two bacteria, soluble intercellular cell adhesion molecule-1 (sICAM-1), soluble vascular cell adhesion molecule-1 (sVCAM-1) and E-selectin were measured in coronary heart disease (CHD) patients ( n  = 193) and age- and sex-matched controls ( n  = 193). Two different serological methods were used for the detection of Chlamydia antibodies: Labsystems microimmunofluorescence to detect species-specific C. pneumoniae antibodies and Medac's recombinant enzyme-linked immunosorbent assay to detect genus-specific lipopolysaccharide antibodies.
Results   The concentrations of sICAM-1 and E-selectin were higher in CHD patients with positive vs. negative Chlamydia lipopolysaccharide IgA ( P  = 0.044 for both). H. pylori antibodies alone did not predict raised levels of sCAMs, but in CHD patients sICAM-1 was increased with IgA seropositivity to both bacteria compared to double seronegativity ( P  = 0.034). Concentrations of sVCAM-1 were elevated in CHD patients with double IgA seropositivity compared to those with Chlamydia lipopolysaccharide IgA seropositivity alone ( P  = 0.018).
Conclusion   Our results may indicate that C. pneumoniae contributes to increased inflammation in CHD, and that this contribution is even more pronounced when present in combination with H. pylori IgA antibodies.     

Levels of intracellular adhesion molecule-1 and vascular cell adhesion molecule-1 in children with Henoch-Sch?nlein purpura.

BACKGROUND AND PURPOSE: Henoch-Sch?nlein purpura (HSP) is a small vessel vasculitis. Soluble adhesion molecules play a very important role in the immuno-inflammatory reaction of damaged vascular tissues. This study investigated the prognostic and diagnostic potential of soluble intracellular adhesion molecule-1 (sICAM-1) and vascular cell adhesion molecule-1 (sVCAM-1) in HSP. METHODS: Serum levels of sICAM-1 and sVCAM-1 were studied in 26 children with HSP. Paired blood samples (during acute and convalescent stages) were collected from 17 of the children and assayed by enzyme-linked immunosorbent assay. Correlations with clinical manifestations were examined. Seventeen healthy children served as controls. RESULTS: Both sICAM-1 and sVCAM-1 were significantly elevated at the acute stage compared with the remission stage of HSP patients versus controls (p=0.006 and p=0.0173, respectively). CONCLUSIONS: Although the levels of sICAM-1 and sVCAM-1 were not correlated with the severity of clinical manifestations in HSP, these soluble adhesion molecules may serve as diagnostic markers.     

Soluble cell adhesion molecules and von Willebrand factor in children with Kawasaki disease.

Fifty-nine children with acute Kawasaki disease (KD), a childhood vasculitis, were compared with 35 children with fever due to infection and 48 healthy children. Levels of soluble E-selectin (sE-selectin), soluble intercellular adhesion molecule-1 (sICAM-1), and soluble vascular cell adhesion molecule-1 (sVCAM-1) in the healthy children were double those found in adults. All three soluble cell adhesion molecules and von Willebrand factor (vWF) were higher in the children with KD than in the healthy children, but only sE-selectin, a marker for activated endothelial cells, and sICAM-1 were higher than in the febrile children. The high levels of vWF in KD appear to reflect the prominent acute-phase reaction. This information can help us to understand further the complex interactions between cytokines, circulating inflammatory cells and the vascular endothelium, and may lead to new therapeutic avenues in KD and other inflammatory diseases and vasculitides.     

Microplate ELISAs for soluble VCAM-1 and ICAM-1

Soluble vascular cell adhesion molecule (sVCAM-1) and soluble intercellular adhesion molecule (sICAM-1) are adhesion molecules that are detectable in the serum of patients with cancer, cardiovascular diseases (CVD), and type 2 diabetes. This report describes enzyme-linked immunosorbent assays (ELISAs) on microplates for sVCAM-1 and sICAM-1. The ELISAs have the sandwich test format; polyclonal antibodies are coated on microwells and a one-step procedure is used in which the serum specimen and detecting antibody are added simultaneously to an antibody-coated well. These assays both use HRP-conjugated sheep anti-mouse-IgG to generate the color for quantification. Sensitivities for detecting sVCAM-1 and sICAM-1 are 49 and 40 ng/ml, respectively. Coefficients of variation for within-day and day-to-day replicate analyses are <10%. Results by these in-house ELISAs for serum sVCAM-1 and sICAM-1 compared well with those obtained with commercial kits from R&D Systems, Inc. (correlation coefficients = 0.98 and 0.99 for sVCAM-1 and sICAM-1, respectively). Reference values for serum sVCAM-1 and sICAM-1 levels were measured in 369 apparently healthy Chinese adults, age 30 to 79 yr. There was no significant effect of gender on the reference values for sVCAM-1 or sICAM-1. Serum sVCAM-1 levels (mean +/- SD) were higher in subjects 60 yr old (625 +/- 126 ng/ml), compared to those <60 yr old (525 +/- 110 ng/ml) (p <0.001). Age did not significantly affect the reference values for serum sICAM-1 levels (mean +/- SD, 249 +/- 86 ng/ml). The authors believe that these simple, inexpensive ELISAs will be useful for assessing the risks for development of cancer, CVD, and type 2 diabetes.     

Levels of soluble VCAM-1, soluble ICAM-1, and soluble E-selectin during disease exacerbations in patients with systemic lupus erythematosus (SLE); a long term prospective study.

Active SLE is characterized by immune deposits and subsequent vascular inflammation in many organs. Expression and up-regulation of adhesion molecules is basic to migration of inflammatory cells into the tissues. Recently, soluble isoforms of these molecules have been described which might be an expression of their up-regulation in the tissues and, as such, of disease activity. The purpose of this study was to evaluate whether changes in levels of soluble adhesion molecules reflect disease activity. We analysed serial sera in a 6-month period preceding 22 consecutive exacerbations of SLE for levels of soluble vascular cell adhesion molecule-1 (sVCAM-1), soluble intercellular adhesion molecule-1 (sICAM-1), and sE-selectin. Levels were related to clinical disease activity (SLEDAI), and levels of anti-dsDNA and complement. At the time of maximal disease activity, levels of sVCAM-1 in patients with SLE were higher than those in controls (P < 0.0001), levels in patients with renal involvement being higher than in those without (P < 0.02). Levels of sVCAM-1 correlated with SLEDAI scores (P < 0.05) and, inversely, with levels of C3 (P = 0.01). In addition, in the presence of anti-dsDNA, levels of sVCAM-1 tended to correlate with levels of these autoantibodies (P < 0.1). Levels of sICAM-1 were normal and sE-selectin levels even decreased compared with controls. Levels of sVCAM-1 were higher at the moment of relapse (P = 0.001) than at 6 months before this time point. This rise correlated with the rise in SLEDAI score (P < 0.02). Levels of sICAM-1 and sE-selectin did not rise, and remained in the normal range in all exacerbations studied. In conclusion, in contrast to sICAM-1 and sE-selectin, levels of sVCAM-1 are increased, rise parallel to disease activity during exacerbations in SLE, and are associated with decreasing levels of complement factors. This favours the hypothesis of immune deposit formation, activation of the complement cascade and activation of endothelial cells. Concurrent up-regulation of vascular adhesion molecules may thus result in transmigration of activated inflammatory cells inducing tissue damage.     

Maternal serum levels of VCAM-1, ICAM-1 and E-selectin in preeclampsia

Endothelial dysfunction is thought to be a central pathogenic feature in preeclampsia on the basis of elevated adhesion molecules. The aim of the present study was to compare the levels of soluble vascular cell adhesion molecule-1 (sVCAM-1), intercellular adhesion molecule-1 (sICAM-1) and E-selectin (sE-selectin) in sera of normal and preeclamptic pregnancies. We studied the serum levels of sVCAM-1, sICAM-1 and sE-selectin in normal pregnant women (n=63), mild preeclampsia (n=33) and severe preeclampsia (n=82). Concentrations of soluble adhesion molecules were determined with enzyme-linked immunoassay (ELISA). Serum concentrations of sVCAM-1 were significantly higher in both mild (p=0.004) and severe preeclampsia (p=0.000) than normal pregnancy. There were also significant differences in sVCAM- 1 levels between mild and severe preeclampsia (p=0.002). sICAM-1 levels of severe preeclampsia were statistically different from those of normal pregnancy (p=0.038). Levels of sE-selectin were elevated in both mild (p=0.011) and severe preeclampsia (p=0.000) compared to normal pregnancy, but no statistical difference between the mild and severe preeclampsia (p=0.345). These results suggest that all three soluble adhesion molecules are increased in severe preeclampsia, and sVCAM-1 among them may be useful in predicting the severity of preeclampsia.     

Reduction of soluble adhesion molecules (sICAM-1, sVCAM-1, and sE-selectin) and vascular endothelial growth factor levels in serum of rheumatoid arthritis patients following multiple intravenous infusions of infliximab

INTRODUCTION: The purpose of this study was to determine the effect of repeated infusions of infliximab, a chimeric anti-tumor necrosis factor (anti-TNF)-alpha antibody, on the levels of soluble adhesion molecules and vascular endothelial growth factor (VEGF) in patients with active rheumatoid arthritis (RA). MATERIALS AND METHODS: The treatment design consisted of 9 infusions of infliximab (3 mg/kg) at weeks 0, 2, 6, and every 8 weeks thereafter. All patients had been receiving methotrexate (MTX; 7.5-20 mg/week). Serum levels of soluble intercellular adhesion molecule (sICAM)-1, vascular cell adhesion molecule (sVCAM)-1, E-selectin (sE-selectin), and VEGF were measured by ELISA at weeks 0, 2, 6, 14, and 38 prior to infusion, and at week 62. RESULTS: A remarkable decrease in serum sICAM-1 (p<0.001), sVCAM-1 (p<0.01), sE-selectin (p<0.01) and VEGF (p<0.001) levels was observed in RA patients after the initial dose of infliximab. The second administration of the drug was followed by an even more significant suppression of serum sICAM-1, sVCAM-1, sE-selectin, and VEGF (p<0.001 in all cases). Further infliximab infusions also significantly reduced serum soluble adhesion molecules and VEGF concentrations, although these were less effective. Infliximab treatment induced a significant decrease in the number of monocytes observed until the end of the study. CONCLUSIONS: Our study, besides a rapid suppression of disease activity, showed that serum soluble adhesion molecules and VEGF concentrations are down-regulated following anti-TNF-alpha antibody therapy combined with MTX. Repeated doses of infliximab sustained the reductions in the soluble adhesion molecules and VEGF concentrations, although they were less effective than the first and second infusions of infliximab.     

Changes in plasma levels of adhesion molecules after percutaneous mitral balloon valvuloplasty.

BACKGROUND: Adhesion molecules are expressed on vascular endothelium and on immune and inflammatory cells. Recently increased levels of adhesion molecules have been shown in patients with rheumatic mitral stenosis. This study examined the serum levels of the adhesion molecules intercellular adhesion molecule 1 (ICAM-1), vascular cell adhesion molecule 1 (VCAM-1), and E-selectin in patients with rheumatic mitral stenosis and the effects of percutaneous mitral balloon valvuloplasty (PMBV) on these adhesion molecules. MATERIALS AND METHODS: Thirty five patients (3 men, 32 women, mean age 39+/-5 years) with severe rheumatic mitral stenosis who underwent percutaneous balloon mitral valvuloplasty, and 35 age and sex matched healthy control subjects were included in the study. Serum levels of ICAM-1, VCAM-1, and E-selectin were measured in all patients who underwent PMBV and in all control subjects. Blood samples were taken for measurement of adhesion molecules immediately before and 24 h after the mitral balloon valvuloplasty. RESULTS: The plasma levels of soluble adhesion molecules E-selectin, ICAM-1 and VCAM-1 were significantly elevated in patients with mitral stenosis compared to control subjects: E-selectin, 97+/-59 vs. 45+/-24 ng/ml (P=.001), sICAM-1, 874+/-301 ng/ml vs. 238+/-82 ng/ml (P<.0001); sVCAM-1, 3056+/-763 ng/ml vs. 985+/-298 ng/ml (P<.0001). Plasma levels of VCAM-1 significantly increased 24 h after the valvuloplasty procedure (3056+/-763 ng/ml vs. 3570+/-1225 ng/ml P=.013). Plasma levels of E-selectin showed a significant decrease after PMBV (97+/-59 vs. 70+/-58 ng/ml, P=.043) and plasma levels of ICAM-1 did not show any change after PMBV (874+/-301 vs. 944+/-377 ng/ml, P=.356). CONCLUSION: Cellular adhesion molecules, sICAM-1, E-selectin, sVCAM-1 have shown changes in different directions in response to PMBV. These results necessitate further studies to clarify the mechanism underlying the association between adhesion molecules and PMBV as well as rheumatic mitral stenosis.